These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1123 related articles for article (PubMed ID: 6996812)

  • 21. Infusion versus perfusion.
    Golomb FM
    Aktuelle Probl Chir; 1970; 14():835-57. PubMed ID: 4124391
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

  • 23. Relationship of dose schedules to the effectiveness of adjuvant chemotherapy.
    Humphreys SR; Karrer K
    Cancer Chemother Rep; 1970 Dec; 54(6):379-92. PubMed ID: 5527021
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.
    Serano RD; Sigel CW; Nichol CA; Bigner DD
    Cancer Treat Rep; 1982 Jan; 66(1):99-106. PubMed ID: 6272992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
    Mattox DE; Clark GM; Balcerzak SP; O'Bryan RM; Oishi N; Stuckey WJ
    Invest New Drugs; 1984; 2(4):405-7. PubMed ID: 6511243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
    Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
    Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
    [No Abstract]   [Full Text] [Related]  

  • 27. Thioproline (Norgamem): a useless drug in the treatment of squamous cell carcinoma.
    Alberto P
    Eur J Cancer Clin Oncol; 1981 Sep; 17(9):1061-2. PubMed ID: 7198987
    [No Abstract]   [Full Text] [Related]  

  • 28. Human plasma and amino acids as moderators of uptake and metabolic consequences of antifolates in WIL-2 and human leukemia cells.
    Fyfe MJ; Sedwick WD; Brown OE; Laszlo J
    J Natl Cancer Inst; 1981 Mar; 66(3):445-51. PubMed ID: 6937701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vinblastine, methotrexate, bleomycin, in the management of head and neck cancer.
    Vanhaelen C; Bertrand M; De Jager R; Kenis Y
    Eur J Cancer (1965); 1979 Nov; 15(11):1315-8. PubMed ID: 93540
    [No Abstract]   [Full Text] [Related]  

  • 30. Feasibility study of combining metronidazole with chemotherapy.
    Stewart DJ; Maroun JA; Young V; Crook AF; Hopkins HS; Yan RC; Richard MT; Hugenholtz H; Bélanger R; Heringer R
    J Clin Oncol; 1983 Jan; 1(1):17-23. PubMed ID: 6422002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma.
    Lynch GR; Gralla RJ; Kelsen DP; Casper ES; Stoopler MB; Golbey RB
    Cancer Clin Trials; 1981; 4(3):273-6. PubMed ID: 6974611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent.
    Sasaki Y; Kjellén E; Ekblad L; Wahlberg P; Mineta H; Wennerberg J
    Oral Oncol; 2012 Jan; 48(1):61-6. PubMed ID: 21963040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of advanced non-small cell lung cancer with bisantrene.
    Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
    Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
    [No Abstract]   [Full Text] [Related]  

  • 34. [A phase II study of NK171 (etoposide)].
    Kimura K; Niitani H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
    Haas CD; Baker L; Thigpen T
    Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung.
    Cappelaere P; Guiochet N; Bastit P; Favre R; Vanderburg M; Goupil A; Chauvergne J; Thomas D; Van Glabbeke M; Armand JP
    Eur J Cancer; 1993; 29A(8):1216. PubMed ID: 8518037
    [No Abstract]   [Full Text] [Related]  

  • 37. Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
    Browman GP; Archibald SD; Young JE; Hryniuk WM; Russell R; Kiehl K; Levine MN
    J Clin Oncol; 1983 Dec; 1(12):787-92. PubMed ID: 6366132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moderate-dose methotrexate in head and neck cancer.
    Advani SH; Mehta AR; Rao MR; Fakih AR; Sanghvi VD; Nair CN; Gopal R
    Oncology; 1981; 38(6):329-33. PubMed ID: 6975453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with emetine hydrochloride (NSC 33669) as an antitumor agent.
    Panettiere F; Coltman CA
    Cancer; 1971 Apr; 27(4):835-41. PubMed ID: 4929936
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II trial of bisantrene in advanced epidermoid carcinoma of the head and neck.
    Forastiere AA; Crain SM; Garbino C; Tipping SJ; Perry DJ; Kasdorf H; Van Echo DA
    Cancer Treat Rep; 1984 Apr; 68(4):687-8. PubMed ID: 6713424
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.